2,4,4-二氧杂-1,3,7-三氮杂螺[4-]叔丁基-7-羧酸叔丁酯 | 887120-96-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 2,4,4-二氧杂-1,3,7-三氮杂螺[4-]叔丁基-7-羧酸叔丁酯
• 英文名称: 7-tert-butyloxycarbonyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
• 英文别名: tert-butyl 2,4-dioxo-1,3,7-triazaspiro[4.5]decane-7-carboxylate；tert-butyl 2,4-dioxo-1,3,9-triazaspiro[4.5]decane-9-carboxylate
• CAS: 887120-96-9
• 化学式: C₁₂H₁₉N₃O₄
• mdl: MFCD08752480
• 分子量: 269.301
• InChiKey: UDAAVVGTVULJRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 储存条件：
  存储条件：2-8°C，密封保存，干燥环境。

反应信息

• 作为反应物：
  描述：

  2,4,4-二氧杂-1,3,7-三氮杂螺[4-]叔丁基-7-羧酸叔丁酯 在 盐酸 、 三乙酰氧基硼氢化钠 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 7-{1-[(2-amino-1-benzothien-3-yl)carbonyl]piperidin-4-yl}-3-ethyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

  摘要：

  Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the spiro-lactone ring and the benzothiophene portion of the molecule. Spiro-imide derivative 8c containing a 6-methylthieno[2,3-b]pyridine core exhibited potent ACC inhibitory activity and favorable pharmacokinetic profiles in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.047
• 作为产物：
  描述：

  N-叔丁氧羰基-3-哌啶酮 、 ammonium carbonate 在 三甲基氰硅烷 作用下， 以 甲醇 、 水 为溶剂， 以67 %的产率得到2,4,4-二氧杂-1,3,7-三氮杂螺[4-]叔丁基-7-羧酸叔丁酯
  参考文献：
  名称：

  AhR抑制剂

  摘要：

  本公开涉及一种如式(I)所示的化合物或其药学上可接受的盐，其作为AhR抑制剂的用途及制备方法。

  公开号：

  CN114835687A

文献信息

• SPIRO-RING COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2128163A1

  公开（公告）日：2009-12-02

  The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.

  本发明旨在提供一种具有乙酰辅酶A羧化酶（ACC）抑制作用的化合物，该化合物对于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌少症、癌症等具有卓越疗效。 本发明提供一种由以下式（I）表示的化合物： 其中 R1是氢原子或取代基； 环P是可选择取代的含氮芳香杂环； 环Q是可选择进一步取代的5-至7-成员的含氮非芳香杂环；和 环R是可选择融合的5-至7-成员的非芳香环，进一步可选择取代， 或其盐。
• SPIRO-CYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1911753A1

  公开（公告）日：2008-04-16

  The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

  本发明提供了一种由以下式（I）表示的化合物： 其中 E是一个可选择地取代的环状基团； D是一个羰基团或磺酰基团； A是CH或N； 环P是一个可选择进一步取代的5至7元环； 环Q是一个可选择进一步取代的5至7元非芳香环； 环R是一个可选择进一步取代和可选择缩合的5至7元非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等的预防或治疗具有用处，并且在功效、持续活性、特异性、低毒性等方面具有优越性能。
• Microwave-assisted synthesis of functionalized spirohydantoins as 3-D privileged fragments for scouting the chemical space
  作者：Hugues Prevet、Marion Flipo、Pascal Roussel、Benoit Deprez、Nicolas Willand

  DOI：10.1016/j.tetlet.2016.05.065

  日期：2016.6

  protein–protein interactions, it is required to enrich current fragment libraries with new and original 3D privileged fragments. Our goal was to develop a rapid microwave-assisted synthesis of 27 new privileged spirohydantoin fragments. Among them 24 compounds showed a high water solubility. These molecules were plotted according to the normalized principal moments of inertia of their minimized conformers

  基于片段的药物设计已成功应用于大量蛋白质，但是，为了将这一概念扩展到最苛刻的目标，例如蛋白质与蛋白质的相互作用，需要使用新的和原始的3D特权丰富当前的片段库碎片。我们的目标是开发微波辅助快速合成27个新的螺乙内酰脲片段的方法。其中24种化合物显示出高水溶性。这些分子是根据其最小化构象异构体的归一化主要惯性矩绘制的，并且大多数化合物都倾向于占据三角形图中人口不足的区域。最后，我们证明了乙内酰脲环可以选择性地为N-单烷基化提供了快速官能化的进一步途径。
• Lactam compounds and their use as pharmaceuticals
  申请人：Yao Wenqing

  公开号：US20060116382A1

  公开（公告）日：2006-06-01

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂、矿物质皮质激素受体（MR）的拮抗剂以及其制药组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性有关的各种疾病和/或与醛固酮过多相关的疾病。
• LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
  申请人：Yao Wenqing

  公开号：US20090291946A1

  公开（公告）日：2009-11-26

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶类型1的抑制剂、矿物质皮质激素受体（MR）的拮抗剂及其制药组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶类型1的表达或活性相关的各种疾病和/或与醛固酮过多相关的疾病。